Status:
UNKNOWN
Matrix Metalloproteinases Neutralizing Agents in Oral Lichen Planus
Lead Sponsor:
Jaylane kadry Ghonima
Conditions:
Oral Lichen Planus
Eligibility:
All Genders
25+ years
Phase:
EARLY_PHASE1
Brief Summary
The current study will be conducted to evaluate the effectiveness of matrix metalloproteinases inhibitors on erosive oral lichen planus.
Detailed Description
Matrix metalloproteinases inhibitor (Orochem) will be given to patients with Oral erosive lichen planus three times daily for 3 weeks. Then the subjective discomfort and pain severity as well as the o...
Eligibility Criteria
Inclusion
- patients diagnosed with erosive OLP confirmed with a biopsy.
- patients should have symptomatic lesions
Exclusion
- Patients who were under anticoagulant medications, suffering from any systemic diseases or having any physical or mental abnormality, pregnant and lactating women, smokers.
Key Trial Info
Start Date :
January 1 2020
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
July 1 2020
Estimated Enrollment :
40 Patients enrolled
Trial Details
Trial ID
NCT04336488
Start Date
January 1 2020
End Date
July 1 2020
Last Update
June 19 2020
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
periodontology department, Faculty of dentistry, Alexandria University
Alexandria, Egypt, 21500